| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442038 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
In refractory MCC, tumour location within the colon is not prognostic, but is strongly predictive of PFS benefit from cetuximab therapy. Additional research is needed to understand the molecular differences between RC and LC and their interaction with EGFR inhibition.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S.Y. Brulé, D.J. Jonker, C.S. Karapetis, C.J. O'Callaghan, M.J. Moore, R. Wong, N.C. Tebbutt, Cr. Underhill, D. Yip, J.R. Zalcberg, D. Tu, R.A. Goodwin,